Dr. Perez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
593 Eddy St
Providence, RI 02903Phone+1 401-444-8450Fax+1 401-444-5088
Education & Training
Brown UniversityFellowship, Hematology and Medical Oncology, 2010
George Washington University School of Medicine and Health SciencesClass of 2004
Certifications & Licensure
MA State Medical License 2015 - 2026
RI State Medical License 2005 - 2026- American Board of Internal Medicine Medical Oncology
Clinical Trials
- BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Start of enrollment: 2014 Aug 01
- Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis Start of enrollment: 2013 May 01
- Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer Start of enrollment: 2018 Dec 05
- Join now to see all
Publications & Presentations
PubMed
- 192 citationsMicroenvironment drives cell state, plasticity, and drug response in pancreatic cancer.Srivatsan Raghavan, Peter S Winter, Andrew W Navia, Hannah L Williams, Alan DenAdel
Cell. 2021-12-09 - 130 citationsClinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma.Jorge J. Castillo, Eric S. Winer, Dariusz Stachurski, Kimberly Perez, Melhem Jabbour
Leukemia & Lymphoma. 2010-11-15 - 10 citationsSystemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.Jaydira Del Rivero, Kimberly Perez, Erin B Kennedy, Erik S Mittra, Namrata Vijayvergia
Journal of Clinical Oncology. 2023-11-10
Journal Articles
- Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic CancerRichard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature
Lectures
- Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Phase 1b study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Dana-Farber Cancer Institute, Brigham and Women''s Hospital Designated as Rare Disease Clinical CenterJune 29th, 2022- Dana-Farber Cancer Institute/Brigham and Women’s Hospital Designated as Rare Disease Clinical Center for Pheochromocytoma &June 28th, 2022
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic CancerJanuary 27th, 2020- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
